Tandem high-dose chemotherapy in high-risk primary breast cancer: A multivariate analysis and a matched-pair comparison with standard-dose chemotherapy
Open Access
- 1 June 2001
- journal article
- research article
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 7 (6) , 332-342
- https://doi.org/10.1016/s1083-8791(01)80004-5
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trialThe Lancet, 2000
- Evaluation of the Predictive Value of Her-2/neu Overexpression and p53 Mutations in High-Risk Primary Breast Cancer Patients Treated With High-Dose Chemotherapy and Autologous Stem-Cell TransplantationJournal of Clinical Oncology, 2000
- Randomized Trial of High-Dose Chemotherapy and Blood Cell Autografts for High-Risk Primary Breast CarcinomaJNCI Journal of the National Cancer Institute, 2000
- Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.Journal of Clinical Oncology, 1998
- Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvementThe Lancet, 1998
- Immunomagnetic selection of CD34+peripheral blood stem cells for autografting in patients with breast cancerBritish Journal of Haematology, 1997
- Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results.Journal of Clinical Oncology, 1997
- Large‐bore central venous catheters for the collection of peripheral blood stem cellsJournal of Clinical Apheresis, 1995
- High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer.Journal of Clinical Oncology, 1993
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958